November 13, 2026 05:33 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Owaisi, Chandrashekhar Azad join hands to challenge BJP in 2027 UP elections | Bihar shocker: Gang-rape survivor thrown off building roof in fresh attack | J&K horror: Two missing SPOs found dead with bullet wounds in Kishtwar | Two missing SPOs found dead with bullet wounds in J&K's Kishtwar | Owaisi, Chandrashekhar Azad join hands to challenge BJP in 2027 UP polls | At least 3 CRPF personnel injured as terrorists open fire on security forces in Jammu and Kashmir's Kulgam | Hijack threat on Air India flight sparks security alert at Kolkata airport before take-off | TMC Canning Paschim MLA Paresh Ram Das arrested at Kolkata airport in rape, extortion cases | Megaspeed breaks silence on Nvidia CEO Jensen Huang row, denies illegal China chip transfers | Nvidia CEO Jensen Huang admits extramarital affair amid shocking Chinese spy allegation
Corona Remedies
Corona Remedies listed at 38% premium. Photo: ChatGPT

Corona Remedies storms Dalal Street! Shares list at 38% premium on debut

| @indiablooms | Dec 15, 2025, at 11:19 am

Mumbai/IBNS: Pharmaceutical firm Corona Remedies made a strong debut on the stock market on Monday, listing at a 38% premium over its IPO price on the National Stock Exchange (NSE), media reports said.

The company’s shares were listed at ₹1,470 apiece on the NSE, marking a 38.42% premium over the issue price.

On the BSE, the stock debuted at ₹1,452 per share, a 36.72% premium.

The ₹655.37-crore IPO, which was entirely an offer for sale, had a price band of ₹1,008–1,062 per share and was open for subscription from December 8 to 10.

Headquartered in Ahmedabad, Gujarat, Corona Remedies is an Indian pharmaceutical company with a strong presence in branded generics, catering to both chronic and acute therapy segments.

The robust listing underscored strong investor confidence in the company’s growth outlook and financial performance, reflecting sustained demand for quality pharma IPOs in the Indian market.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.